Correlation between poliovirus type 1 Mahoney replication in blood cells and neurovirulence

Journal of Virology

Volumn 70, Issue 9, 1996, Pages 6486-6492

  Freistadt, M S ^a   Eberle, K E ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONONUCLEAR CELL; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS INFECTIVITY; VIRUS REPLICATION;

EID: 0029791794     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.9.6486-6492.1996     Document Type: Article

References (50)

1. Agol, V., V. Grachev, S. Drozdov, M. Kolesnikova, V. Kozlov, N. Ralph, L. Romanova, E. Tolskaya, A. Tyufanov, and E. Viktorova. 1984. Construction and properties of intertypic poliovirus recombinants: first approximation mapping of the major determinants of neurovirulence. Virology 136:41-55.
2. Almond, J., G. Westrop, D. Evans, G. Dunn, P. Minor, D. Magrath, and G. Schild. 1987. Studies on the attenuation of the Sabin type 3 oral polio vaccine. J. Virol. Methods 17:183-189.
3. Almond, J., G. Westrop, K. Wareham, M. Skinner, D. Evans, D. Magrath, G. Schild, and P. Minor. 1987. Studies on the genetic basis of attenuation of the Sabin type 3 poliovirus vaccine. Biochem. Soc. Symp. 53:85-90.
4. Aronson, J. F., N. K. Herzog, and T. R. Jerrells. 1994. Pathological and virological features of arenavirus disease in guinea pig: comparison of two pichinde virus strains. Am. J. Pathol. 145:228-235.
5. Blyn, L. B., R. Chen, B. L. Semler, and E. Ehrenfeld. 1995. Host cell proteins binding to domain IV of the 5′ noncoding region of poliovirus RNA. J. Virol. 69:4381-4389.
6. Bodian, D. 1954. Viremia in experimental poliomyelitis. Am. J. Hyg. 60:339-357.
7. Bouchard, M. J., D.-H. Lam, and V. R. Racaniello. 1995. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J. Virol. 69:4972-4978.
8. Carp, R., S. Plotkin, T. Norton, and H. Koprowski. 1963. Modification of an attenuated type 2 polio vaccine following passage at 23 degrees C. Proc. Soc. Exp. Biol. Med. 112:251-256.
9. Christodoulou, C., F. Colbere-Garapin, A. Macadam, L. F. Taffs, S. Marsden, P. Minor, and F. Horaud. 1990. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J. Virol. 64:4922-4929.
10. Clements, J., M. Zink, O. Narayan, and D. Gabuzda. 1994. Lentivirus infection of macrophages. Immunol. Ser. 60:589-600.
11. Eberle, K. E., V. T. Nguyen, and M. S. Freistadt. 1995. Low levels of poliovirus replication in primary human monocytes: possible interactions with lymphocytes. Arch. Virol. 140:2135-2150.
12. Emini, E. A., B. A. Jameson, and E. Wimmer. 1983. Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides. Nature (London) 304:699-703.
13. Freistadt, M. S. 1994. Distribution of the poliovirus receptor in human tissue, p. 455-461. In E. Wimmer (ed.), Cellular receptors for animal viruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
14. Freistadt, M. S., and K. E. Eberle. Submitted for publication.
15. Freistadt, M. S., H. B. Fleit, and E. Wimmer. 1993. Poliovirus receptor on human blood cells: a possible extraneural site of poliovirus replication. Virology 195:798-803.
16. Freistadt, M. S., G. Kaplan, and V. R. Racaniello. 1990. Heterogeneous expression of poliovirus receptor-related proteins in human cells and tissues. Mol. Cell. Biol. 10:5700-5706.
17. Freistadt, M. S., D. A. Stoltz, and K. E. Eberle. 1994. Role of poliovirus receptors in the spread of the infection, p. 37-47. In M. C. Dalakas et al. (ed.), The post-polio syndrome: advances in the pathogenesis and treatment. New York Academy of Sciences, New York.
18. Hellen, C., G. Witherell, M. Schmid, S. Shin, T. Pestova, A. Gil, and E. Wimmer. 1993. A cytoplasmic 57-kDa protein that is required for translation of picornavirus RNA by internal ribosomal entry is identical to the nuclear pyrimidine tract-binding protein. Proc. Natl. Acad. Sci. USA 90:7642-7646.
19. Horstmann, D., E. Opton, R. Klemperer, B. Llado, and A. Vignec. 1964. Viremia in infants vaccinated with oral poliovirus vaccine (Sabin). Am. J. Hyg. 79:47-63.
20. Ibanez, C. E., R. Schrier, P. Ghazal, C. Wiley, and J. A. Nelson. 1992. Human cytomegalovirus productively infects primary differentiated macrophages, J. Virol. 65:6581-6588.
21. Jang, S. K., T. Pestova, C. U. T. Hellen, G. W. Witherell, and E. Wimmer. 1990. Cap-independent translation of picornavirus RNAs: structure and function of the internal ribosomal entry site. Enzyme (Basel) 44:292-309.
22. Joseph, B. S., P. W. Lampert, and M. B. A. Oldstone. 1975. Replication and persistence of measles virus in defined subpopulation of human leukocytes. J. Virol. 16:1638-1649.
23. Kaplan, A. S. 1955. Comparison of susceptible and resistant cells to infection with poliomyelitis virus. Ann. N. Y. Acad. Sci. 61:830-839.
24. Kawamura, N., M. Kohara, S. Abe, T. Komatsu, K. Tago, M. Arita, and A. Nomoto. 1989. Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J. Virol. 63:1302-1309.
25. Kohara, M., S. Abe, T. Komatsu, K. Tago, M. Arita, and A. Nomoto. 1988. A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain. J. Virol. 62:2828-2835.
26. Koike, S., H. Horie, I. Ise, A. Okitsu, M. Yoshida, N. Iizuka, K. Takeuchi, T. Takegami, and A. Nomoto. 1990. The poliovirus receptor protein is produced both as membrane-bound and secreted forms. EMBO J. 9:3217-3224.
27. Macadam, A. J., G. Ferguson, C. Arnold, and P. D. Minor. 1991. An assembly defect as a result of an attenuating mutation in the capsid protein of the poliovirus type 3 vaccine strain. J. Virol. 72:2475-2481.
28. Maynell, L. A., K. Kirkegaard, and M. W. Klymkowsky. 1992. Inhibition of poliovirus RNA synthesis by brefeldin A. J. Virol. 66:1985-1994.
29. McNearney, T., Z. Hornickova, R. Markham, A. Birdwell, M. Arens, A. Saah, and L. Ratner. 1992. Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc. Natl. Acad. Sci. USA 89:10247-10251.
30. Melnick, J., R. Proctor, A. Ocampo, A. Diwan, and E. Ben-Porath. 1961. Viremia after administration of live poliovirus vaccine. Bacteriol. Proc. 61: 145. (Abstract.)
31. Melnick, J. L. 1990. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p. 549-604. In B. Fields (ed.), Virology. Raven Press, New York.
32. Mendelsohn, C., B. Johnson, K. A. Lionetti, P. Nobis, E. Wimmer, and V. R. Racaniello. 1986. Transformation of a human poliovirus receptor gene into mouse cells. Proc. Natl. Acad. Sci. USA 83:7845-7849.
33. Mendelsohn, C. L., E. Wimmer, and V. R. Racaniello. 1989. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56:855-865.
34. Minor, P. 1992. The molecular biology of polio vaccines. J. Gen. Virol. 73:3065-3077.
35. Molla, A., A. V. Paul, and E. Wimmer. 1991. Cell-free de novo synthesis of poliovirus. Science 254:1647-1651.
36. Nomoto, A., T. Omata, H. Toyoda, S. Kuge, H. Horie, Y. Kataoka, Y. Genba, Y. Nakano, and N. Imura. 1982. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc. Natl. Acad. Sci. USA 79:5793-5797.
37. Omata, T., M. Kohara, S. Kuge, T. Komatsu, S. Abe, B. L. Semler, A. Kameda, H. Itoh, M. Arita, E. Wimmer, and A. Nomoto. 1986. Genetic analysis of the attenuation phenotype of poliovirus type 1. J. Virol. 58:348-358.
38. Pevear, D., C. Oh, L. Cunningham, M. Calenoff, and B. Jubelt. 1990. Localization of genomic regions specific for the attenuated, mouse-adapted poliovirus type 2 strain W-2. J. Gen. Virol. 71:43-52.
39. Pollard, S. R., G. Dunn, N. Cammack, P. D. Minor, and J. W. Almond. 1989. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J. Virol. 63:4949-4951.
40. Racaniello, V. R. 1988. Poliovirus neurovirulence. Adv. Virus Res. 34:217-246.
41. Ren, R., and V. R. Racaniello. 1992. Human poliovirus receptor gene expression and poliovirus tissue tropism in transgenic mice. J. Virol. 66:296-304.
42. Roberts, J. A. 1963. Histopathogenesis of mousepox. Br. J. Exp. Pathol. 44:465-472.
43. Sabin, A. B. 1955. Characteristics and genetic potentialities of experimentally produced and naturally occurring variants of poliomyelitis virus. Ann. N. Y. Acad. Sci. 61:924-939.
44. Sabin, A. B. 1973. History of the Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1:115-118.
45. Sabin, A. B. 1985. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J. Infect. Dis. 151:420-436.
46. Shepley, M. P., and V. R. Racaniello. 1994. A monoclonal antibody that blocks poliovirus attachment recognizes the lymphocyte homing receptor CD44. J. Virol. 68:1301-1308.
47. Svitkin, Y. V., T. Pestova, S. V. Maslova, and V. I. Agol. 1988. Point mutations modify the response of poliovirus RNA to a translation initiation factor: a comparison of neurovirulent and attenuated strains. Virology 166: 394-404.
48. Swinscow, T. 1978. Statistics at square one, p. 37-38. British Medical Association, London.
49. Todd, R. 1993. Myeloid antigens: section report, p. 739-770, In S. F. Schlossman (ed.), Leucocyte typing V. Oxford University Press, New York.
50. Wimmer, E., C. U. T. Hellen, and X. Cao. 1993. Genetics of poliovirus. Annu. Rev. Genet. 27:353-436.